Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Report: Indian Drug Makers Too Risk-Averse

This article was originally published in PharmAsia News

Executive Summary

PricewaterhouseCoopers, the U.S. accounting/consulting firm, says in a new report that Indian drug makers are not taking the risks they should for creating new treatments. The report cited a basic conflict between drug makers and governments over the price of drugs. The report noted pharmaceutical companies often are flying blind when they attempt to develop a new drug. The report urged governments to adopt policies that spur innovative research, and back that work with good intellectual-property laws. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts